Le Lézard
Classified in: Health, Science and technology
Subjects: Stock Sale/Buyback, Share Issue

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)


Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on February 29, 2024.

One individual was hired by Adicet in February 2024 and granted new hire non-qualified stock options to purchase 7,000 shares of Adicet's common stock with an exercise price of $2.35 per share, the closing price of Adicet's common stock as reported by Nasdaq on February 29, 2024. One-fourth of the shares underlying the employee's option will vest on the one-year anniversary of the recipient's start date and thereafter the remaining three-fourths of the shares underlying the employee's option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to the employee will be fully vested on the fourth anniversary of the recipient's start date, subject to the employee's continued employment with Adicet on such vesting dates.

The above-described award was granted outside of Adicet's stockholder-approved equity incentive plans pursuant to Adicet's 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The award was authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employee entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.


These press releases may also interest you

at 02:00
OKX, a leading crypto exchange and Web3 technology company, has issued updates for May 3, 2024. OKX Successfully Completes GF Token...

at 01:05
BusinessWomen.com, the visionary new platform for female entrepreneurs and professionals, founded by Loes Daniels, entrepreneur and founder of the successful and award winning start-up ExperienceGift, officially goes live today. This platform...

at 01:00
Brett Reeves brings over two decades of experience in traditional finance to BitGo, including executive roles at Citibank, Nomura, and Standard Chartered Bank. BitGo Europe is one of the few digital asset companies with a BaFin license in Germany to...

at 01:00
OKX, a leading Web3 technology company, today announced that it is a platinum sponsor and exclusive ticketing partner with GM VIETNAM (@gmvn_official) for the highly anticipated Vietnam Blockchain Week....

at 00:15
Watlow®, a leading provider of industrial technology and thermal systems, is excited to announce the launch of its new Prime Distributor Program across Europe. This program will provide customers with improved support and easier access to the full...

at 00:00
Leading digital asset exchange Bitrue continues its community-driven approach with the listing of a new Bitcoin Runes token, GPTV?AI?PEPE?KING (GPTV). This follows the recent addition of several other Bitcoin Runes tokens to the platform, including...



News published on and distributed by: